BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis, and biological properties of highly potent cyclic dynorphin A analogues. Analogues cyclized between positions 5 and 11. 1994

J P Meyer, and N Collins, and F D Lung, and P Davis, and T Zalewska, and F Porreca, and H I Yamamura, and V J Hruby
Department of Chemistry, University of Arizona, Tucson 85721.

We have recently reported the synthesis of several cyclic disulfide bridge-containing peptide analogues of dynorphin A (Dyn A), which were conformationally constrained in the putative address segment of the opioid ligand. Several of these analogues, bridged between positions 5 and 11 of Dyn A1-11-NH2, exhibited unexpected selectivities for the kappa and mu receptors of the central over the peripheral nervous systems. In order to further investigate the conformational and topographical requirements for the residues in positions 5 and 11 of these analogues, we have synthesized a systematic series of Dyn A1-11-NH2 analogues incorporating the sulfydryl containing amino acids L- and D-Cys and L- and D-Pen in positions 5 and 11, thus producing 16 cyclic peptides. In addition, Dyn A1-11-NH2, [D-Leu5]Dyn A1-11-NH2, and [D-Lys11]Dyn A1-11-NH2 were synthesized as standards. Several of these cyclic analogues, especially c[Cys5,D-Cys11] Dyn A1-11-NH2, c[Cys5, L- or D-Pen11]Dyn A1-11-NH2, c[Pen5, L-Pen11]Dyn A1-11-NH2 and c[Pen5, L- or D-Cys11]Dyn A1-11-NH2, retained the same affinity and selectivity (vs the mu and delta receptors) as the parent compound Dyn A1-11-NH2 in the guinea pig brain (GPB). These same analogues and most others exhibited a much lower activity in the guinea pig ileum (GPI), thus leading to centrally vs peripherally selective peptides, but showed a different structure-activity relationship than found previously. In a wider scope, this series of analogues also provided new insights into which amino acids (and their configurations) may be used in positions 5 and 11 of Dyn A analogues for high potency and good selectivity at kappa opioid receptors. The results obtained in the GPB suggest that requirements for binding are not the same for the kappa, mu, or delta central receptors.

UI MeSH Term Description Entries
D007082 Ileum The distal and narrowest portion of the SMALL INTESTINE, between the JEJUNUM and the ILEOCECAL VALVE of the LARGE INTESTINE.
D008297 Male Males
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009119 Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments. Inotropism,Muscular Contraction,Contraction, Muscle,Contraction, Muscular,Contractions, Muscle,Contractions, Muscular,Inotropisms,Muscle Contractions,Muscular Contractions
D010456 Peptides, Cyclic Peptides whose amino acid residues are linked together forming a circular chain. Some of them are ANTI-INFECTIVE AGENTS; some are biosynthesized non-ribosomally (PEPTIDE BIOSYNTHESIS, NON-RIBOSOMAL). Circular Peptide,Cyclic Peptide,Cyclic Peptides,Cyclopeptide,Orbitide,Circular Peptides,Cyclopeptides,Orbitides,Peptide, Circular,Peptide, Cyclic,Peptides, Circular
D011957 Receptors, Opioid Cell membrane proteins that bind opioids and trigger intracellular changes which influence the behavior of cells. The endogenous ligands for opioid receptors in mammals include three families of peptides, the enkephalins, endorphins, and dynorphins. The receptor classes include mu, delta, and kappa receptors. Sigma receptors bind several psychoactive substances, including certain opioids, but their endogenous ligands are not known. Endorphin Receptors,Enkephalin Receptors,Narcotic Receptors,Opioid Receptors,Receptors, Endorphin,Receptors, Enkephalin,Receptors, Narcotic,Receptors, Opiate,Endorphin Receptor,Enkephalin Receptor,Normorphine Receptors,Opiate Receptor,Opiate Receptors,Opioid Receptor,Receptors, Normorphine,Receptors, beta-Endorphin,beta-Endorphin Receptor,Receptor, Endorphin,Receptor, Enkephalin,Receptor, Opiate,Receptor, Opioid,Receptor, beta-Endorphin,Receptors, beta Endorphin,beta Endorphin Receptor,beta-Endorphin Receptors
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D004399 Dynorphins A class of opioid peptides including dynorphin A, dynorphin B, and smaller fragments of these peptides. Dynorphins prefer kappa-opioid receptors (RECEPTORS, OPIOID, KAPPA) and have been shown to play a role as central nervous system transmitters. Dynorphin,Dynorphin (1-17),Dynorphin A,Dynorphin A (1-17)
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein

Related Publications

J P Meyer, and N Collins, and F D Lung, and P Davis, and T Zalewska, and F Porreca, and H I Yamamura, and V J Hruby
Design and synthesis of highly potent and selective cyclic dynorphin A analogues.
July 1990, Journal of medicinal chemistry,
J P Meyer, and N Collins, and F D Lung, and P Davis, and T Zalewska, and F Porreca, and H I Yamamura, and V J Hruby
Synthesis and opioid activity of side-chain-to-side-chain cyclic dynorphin A-(1-11) amide analogues cyclized between positions 2 and 5. 1. Substitutions in position 3.
January 2004, Journal of medicinal chemistry,
J P Meyer, and N Collins, and F D Lung, and P Davis, and T Zalewska, and F Porreca, and H I Yamamura, and V J Hruby
Design, synthesis, and biological properties of highly potent epothilone B analogues.
August 2003, Angewandte Chemie (International ed. in English),
J P Meyer, and N Collins, and F D Lung, and P Davis, and T Zalewska, and F Porreca, and H I Yamamura, and V J Hruby
Design, synthesis, and biological properties of highly potent tubulysin D analogues.
January 2007, Chemistry (Weinheim an der Bergstrasse, Germany),
J P Meyer, and N Collins, and F D Lung, and P Davis, and T Zalewska, and F Porreca, and H I Yamamura, and V J Hruby
Design, synthesis, and pharmacological activities of dynorphin A analogues cyclized by ring-closing metathesis.
September 2009, Journal of medicinal chemistry,
J P Meyer, and N Collins, and F D Lung, and P Davis, and T Zalewska, and F Porreca, and H I Yamamura, and V J Hruby
Design and synthesis of highly potent and selective cyclic dynorphin A analogs. 2. New analogs.
March 1993, Journal of medicinal chemistry,
J P Meyer, and N Collins, and F D Lung, and P Davis, and T Zalewska, and F Porreca, and H I Yamamura, and V J Hruby
Synthesis and biological activities of dynorphin A analogues with opioid antagonist properties.
October 1986, Journal of medicinal chemistry,
J P Meyer, and N Collins, and F D Lung, and P Davis, and T Zalewska, and F Porreca, and H I Yamamura, and V J Hruby
Design, synthesis, and biological activities of cyclic lactam peptide analogues of dynorphine A(1-11)-NH2.
March 1996, Journal of medicinal chemistry,
J P Meyer, and N Collins, and F D Lung, and P Davis, and T Zalewska, and F Porreca, and H I Yamamura, and V J Hruby
Design, synthesis, and biological evaluation of novel analogues of archazolid: a highly potent simplified V-ATPase inhibitor.
March 2007, Bioorganic & medicinal chemistry letters,
J P Meyer, and N Collins, and F D Lung, and P Davis, and T Zalewska, and F Porreca, and H I Yamamura, and V J Hruby
Development of highly potent and selective dynorphin A analogues as new medicines.
November 2005, The journal of peptide research : official journal of the American Peptide Society,
Copied contents to your clipboard!